DOXYCYCLINE HYCLATE (DORYX) 75 and 100mg Delayed Release Tablets: Innovator Warner Chilcott Sued another generic player

Innovator Warner Chilcott Limited announced today that its subsidiaries Mayne Pharma have filed a lawsuit against generic company Actavis Elizabeth in the District Court for the District of New Jersey for infringement of Mayne's following Orange Book listed patent for DOXYCYCLINE HYCLATE (DORYX) 75 and 100mg Delayed Release Tablets:
US6958161 (Expiry: Dec 15, 2022): Which covers a modified release preparation having one or more coated core elements, each core element comprising an active ingredient selected from the group consisting of the acid salts of Doxycycline, Tetracycline, Oxytetracycline, Minocycline, Chlortetracycline or Demeclocycline and having a modified release coating, wherein a stabilising coat is provided between each core element and its modified release coating so that, upon in vitro dissolution testing, the amount of active ingredient released at any time on a post-storage dissolution profile is within 40 percentage points of the amount of active ingredient released at any time on a pre-storage dissolution profile..
Earlier, innovator has sued Impax, Mutual Pharma, Mylan Pharma and Sandoz for the infringement of ‘161 patent in District of New Jersey as reported earlier by this blog Here